TIM-3 expression levels have been shown to correlate with resistance to immunotherapies and poor prognosis in many cancer types such as melanoma, HCC, prostate cancer, RCC, colon cancer, bladder cancer, cervical cancer, gastric cancer, and esophageal squamous cell carcinoma (122, 141–149). This evidence concerns the gene HAVCR2 and cancer.